Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer
Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.
Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.